Roche Wins U.S. Approval for New Oral Breast Cancer Drug
BASEL, Switzerland — November 17, 2026 — Swiss pharmaceutical company Roche has secured a significant regulatory victory in the United States after the Food and Drug Administration (FDA) authorized its new oral cancer medicine, Wilserdly, for a specific group of patients with advanced breast cancer. The decision gives the company an opportunity to strengthen its position in the competitive oncology market while introducing another treatment option for patients whose disease has become resistant to hormone-based therapies.
The medicine, known generically as giredestrant, will be prescribed alongside everolimus. Its approval, announced on November 16, covers adults with estrogen receptor-positive, HER2-negative breast cancer carrying an ESR1 gene mutation. Patients must have locally advanced or metastatic disease that has returned following endocrine-based treatment or progressed after at least one endocrine-based treatment regimen for metastatic cancer.
The authorization is particularly relevant to a population that can face diminishing treatment options as cancer cells develop resistance to established hormonal therapies. However, the approval does not extend to every breast cancer patient. Eligibility depends on the tumor’s biological characteristics and confirmation of the relevant genetic mutation.
A New Option for Patients Facing Hormone Therapy Resistance
Hormone receptor-positive breast cancer is driven, in part, by signals involving estrogen receptors. Treatments that interfere with these signals have long played an important role in managing the disease.
Over time, however, some tumors acquire genetic changes that allow them to continue growing despite hormonal treatment. One important mechanism involves mutations in the ESR1 gene, which can alter estrogen receptor activity and reduce the effectiveness of certain endocrine therapies.
Wilserdly belongs to a class of medicines known as selective estrogen receptor degraders, or SERDs. Rather than simply blocking estrogen from interacting with its receptor, the medicine works to inhibit and break down the receptor itself.
The second component, everolimus, acts on a separate biological pathway involved in cancer-cell growth. Combining the two medicines is intended to address different mechanisms contributing to tumor progression.
Roche estimates that ESR1 mutations affect a substantial proportion of patients with hormone receptor-positive metastatic breast cancer. The company has identified the mutation as an important driver of resistance, making genetic testing a central part of selecting suitable patients for treatment.
Clinical Trial Results Behind the FDA Decision
The FDA’s decision was supported by findings from the Phase III evERA Breast Cancer trial, which evaluated giredestrant combined with everolimus against another endocrine treatment combined with the same drug.
The study enrolled 373 participants with advanced estrogen receptor-positive, HER2-negative breast cancer. Of these, 207 had tumors carrying ESR1 mutations, the group particularly relevant to the newly approved treatment.
Among participants with the mutation, median progression-free survival reached 10 months in the giredestrant combination group. Patients receiving the comparison treatment had a median progression-free survival of 5.5 months.
Researchers also reported a 62% reduction in the relative risk of disease progression or death among patients with ESR1-mutated tumors receiving the new combination. The findings were published in The New England Journal of Medicine.
The overall trial population also showed a benefit. Median progression-free survival was 8.8 months among patients receiving giredestrant and everolimus, compared with 5.5 months in the comparison group.
These results offer important evidence of improved disease control. Nevertheless, progression-free survival should not be confused with overall survival. The reported findings do not establish that patients taking the combination will necessarily live longer.
The treatment also carries potential adverse effects. Clinical trial data identified mouth inflammation, diarrhea and anemia among frequently reported problems. FDA prescribing information includes additional warnings, including potential harm to an unborn baby.
An All-Oral Treatment With a Companion Diagnostic
One notable feature of the new regimen is that both medicines can be taken orally. This provides an alternative to treatment approaches involving injections, although patients will still require medical supervision, regular assessments and monitoring for adverse reactions.
The FDA has also authorized the FoundationOne Liquid CDx test as a companion diagnostic to identify patients with ESR1 mutations who may qualify for treatment.
This is an important part of the approval because the medicine is not intended for patients solely on the basis of having advanced breast cancer. Doctors must establish that the relevant mutation is present before selecting the treatment.
According to the prescribing information, the recommended giredestrant dosage is 30 milligrams once daily. Everolimus is administered as part of the combination under its applicable prescribing instructions.
Roche Enters a Competitive and High-Value Market
Beyond its medical significance, the authorization represents an important commercial development for Roche.
The company has placed Wilserdly at the center of its efforts to expand its breast cancer treatment portfolio. The medicine will compete in a market that already includes oral treatment options developed by other major pharmaceutical companies.
According to Reuters, Roche has set a U.S. list price of $22,500 per month. This places the medicine in a high-priced segment of the oncology market, although the actual amount paid by patients will depend on insurance arrangements, financial assistance and other coverage provisions.
The pricing issue is particularly important in the United States, where access to expensive cancer medicines can vary significantly depending on a patient’s insurance coverage and financial circumstances.
Commercial forecasts also indicate considerable interest in the drug’s potential. Estimates reported by Swissinfo suggest revenue of approximately $500 million to $600 million could be possible in 2027, its first full year on the market.
Longer-term projections are considerably more ambitious but differ among analysts. Zurich Cantonal Bank analyst Urban Fritsche has estimated potential peak annual sales of up to CHF14 billion by 2033, while the broader consensus forecast cited in the report stands at approximately CHF4.2 billion. These figures are projections rather than guaranteed revenue.
The opportunity is significant for a company that recorded CHF61.52 billion in total revenue during 2025, including CHF48 billion from pharmaceuticals. A successful launch could contribute to its oncology business, although the drug’s eventual commercial performance will depend on clinical uptake, competition, reimbursement and regulatory developments.
Another FDA Decision Could Expand Its Reach
Roche’s ambitions for giredestrant extend beyond patients with advanced cancer.
The company has also submitted an application seeking approval to use the medicine as an adjuvant treatment for adults with earlier-stage estrogen receptor-positive, HER2-negative breast cancer who face an intermediate or high risk of recurrence.
That application is supported by results from the Phase III lidERA Breast Cancer study and has received Priority Review status from the FDA.
A regulatory decision is expected by November 30, 2026. If authorized, the additional indication could significantly expand the number of patients eligible for treatment by bringing the medicine into an earlier stage of breast cancer management.
The distinction is important: the November 16 authorization applies to a narrowly defined advanced-disease population, while the separate application concerns treatment following surgery in earlier-stage disease. The second indication has not yet been approved.
For Roche, the coming regulatory decision could therefore prove as commercially important as the initial authorization.
A Significant Development, With Further Questions Ahead
The FDA’s approval gives Roche a new opportunity to compete in the rapidly developing field of precision oncology. It also provides an additional treatment option for patients whose breast cancer has progressed despite earlier hormone-based therapy.
However, the medicine’s long-term contribution will depend on more than encouraging clinical trial results. Its effectiveness in routine medical practice, safety profile, affordability and availability will all influence its impact.
The approval is an important advance in treatment options for a defined group of patients, rather than a universal solution for breast cancer. The next regulatory milestone on November 30 could determine whether Wilserdly develops into a treatment with a substantially broader role in breast cancer care.
For the Swiss pharmaceutical group, the immediate challenge will be translating regulatory approval into patient access and sustained commercial success in one of the world’s most competitive healthcare markets.
